Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209804 | 0.84 | ITGB3 (0.68) | ITGB3ITGAV | |
| SCHEMBL6702670 | 0.83 | ITGB3 (0.68) | ITGB3ITGAV | |
| SCHEMBL3232755 | 0.82 | ITGB3 (0.66) | ITGB3ITGAV | |
| SCHEMBL3222279 | 0.81 | ITGB3 (0.69) | ITGB3ITGAV | |
| SCHEMBL3220109 | 0.70 | TSHR (0.49) | ITGB3ITGAV | |
| SCHEMBL5025481 | 0.70 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5029944 | 0.70 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5026293 | 0.70 | ITGB3 (1.00) | ITGB3ITGAV | |
| SCHEMBL5026377 | 0.69 | ITGB3 (0.80) | ITGB3ITGAV | |
| SCHEMBL3221473 | 0.69 | ITGB3 (0.65) | ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077638-A1 | Novel integrin receptor antagonists | BASF AKTIENGESELLCHAFT (DE) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077638-A1 | Novel integrin receptor antagonists | ITGB3, ITGAV, ITGA2B | ITGB3 1/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.